Fulvestrant | Estrogen receptor antagonist
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $62.00 | ||
| 25 mg | $165.00 |
Fulvestrant (129453-61-8) is a 17β-estradiol analog that acts as an estrogen receptor (ER) antagonist and GPR30/GPER agonist with high binding affinity.1,2 First-in-class SERD (selective ER degrader) because it inhibits ER transcriptional activity and leads to its degradation.3 Exhibits mixed neuroprotective activity in vivo.4 Clinically useful option for some advanced breast cancers.5
References:
- Osborne et al. (2004), Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action; Br. J. Cancer 90 (Suppl 1):S2
- Thomas et al. (2005), Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells; Endocrinology 146 624
- Wardley (2002), Fulvestrant: a review of its development, pre-clinical and clinical data; Int. J. Clin. Pract. 56 305
- Castro et al. (2012), Coumestrol has neuroprotective effects before and after cerebral ischemia in female rats; Brain Res. 1474 82
- Blackburn et al. (2018), Fulvestrant for the treatment of advanced breast cancer; Expert Rev. Anticancer Ther. 18 619
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Fulvestrant (129453-61-8) is a 17β-estradiol analog that acts as an estrogen receptor (ER) antagonist and GPR30/GPER agonist with high binding affinity.1,2 First-in-class SERD (selective ER degrader) because it inhibits ER transcriptional activity and leads to its degradation.3 Exhibits mixed neuroprotective activity in vivo.4 Clinically useful option for some advanced breast cancers.5
References:
- Osborne et al. (2004), Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action; Br. J. Cancer 90 (Suppl 1):S2
- Thomas et al. (2005), Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells; Endocrinology 146 624
- Wardley (2002), Fulvestrant: a review of its development, pre-clinical and clinical data; Int. J. Clin. Pract. 56 305
- Castro et al. (2012), Coumestrol has neuroprotective effects before and after cerebral ischemia in female rats; Brain Res. 1474 82
- Blackburn et al. (2018), Fulvestrant for the treatment of advanced breast cancer; Expert Rev. Anticancer Ther. 18 619
Related products
-
Imiquimod | TLR7 Agonist
From $30.00CAS:99011-02-6Catalog Number:10-4230Alternate Name:R837Activity:TLR7 agonistChemical Name:1-(2-Methylpropyl)imidazo[4,5-c]quinolin-4-amineMolecular Weight:240.30Molecular Formula:C14H16N4Solubility:Soluble in DMSO (2 mg/ml with warming)Physical Properties:White solidPurity:>98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Norfluoxetine HCl | Fluoxetine Metabolite
From $60.00CAS:57226-68-3Catalog Number:10-2671Alternate Name:DesmethylfluoxetineActivity:Fluoxetine metaboliteChemical Name:3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine hydrochloride (racemic)Molecular Weight:331.76Molecular Formula:C16H16F3NO HClSolubility:Soluble in DMSO ( up to at least 25 mg/ml)Physical Properties:Beige waxy solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
